Testing for Bowel Cancer

Transforming Bowel Cancer Screening with Proactive Diagnostics

Bowel cancer is one of the most common cancers in the UK and a leading cause of cancer‑related deaths. Early detection significantly improves survival rates, yet many cases are diagnosed only after symptoms develop. Traditional screening methods typically identify bowel cancer once a tumour or advanced polyp has formed, limiting opportunities for early intervention. Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies cancer risk at the molecular level, long before structural changes appear on imaging or during endoscopic examination.

The HrC test represents a new generation of bowel cancer screening—one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into bowel cancer risk than conventional methods alone.

Current Methods for Diagnosing Bowel Cancer

Bowel cancer screening and diagnosis in the UK typically involve several established tools used within the NHS and private healthcare settings:

• Faecal Immunochemical Test (FIT): The primary NHS screening method for adults, used to detect hidden blood in stool.
• Colonoscopy: The gold‑standard diagnostic procedure that allows direct visualisation of the bowel and removal of suspicious polyps.
• Flexible Sigmoidoscopy: A targeted examination of the lower bowel used in some screening pathways.
• CT Colonography (Virtual Colonoscopy): A non‑invasive imaging test used when colonoscopy is unsuitable.
• Biopsy: Tissue samples collected during colonoscopy to confirm malignancy and determine cancer characteristics.

These methods have been essential in improving outcomes, yet they remain reactive—they detect cancer only after visible changes occur.

Limitations of Conventional Bowel Cancer Screening

Despite their value, traditional diagnostic tools present several challenges that can delay or complicate early detection:

• Detection Threshold: Imaging and endoscopy can only identify polyps or tumours once they reach a detectable size, meaning the earliest molecular changes remain hidden.
• False Positives: Inflammation, benign polyps, and haemorrhoids can mimic cancer indicators, leading to unnecessary follow‑up tests and anxiety.
• Invasiveness: Colonoscopy carries risks such as bleeding, perforation, and discomfort, and requires bowel preparation that many people find unpleasant.
• Screening Eligibility: NHS screening is age‑based, meaning younger adults with risk factors may not be screened until symptoms appear.

These limitations highlight the need for a diagnostic tool that identifies cancer risk before a tumour forms.

The HrC Test: A Breakthrough in Early Bowel Cancer Detection

The HrC test introduces a transformative approach to bowel cancer screening by focusing on the earliest biological drivers of cancer. Instead of searching for tumours or polyps, the test isolates and analyses Cancer Stem Cells (CSCs)—the rare cells responsible for initiating cancer development.

A simple 12ml blood sample enables the HrC test to deliver:

• A 12–18 Month Early Warning Window: Detection of cancer‑initiating molecular activity long before imaging or biopsy can identify a mass.
• High Sensitivity and Clear Results: With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
• Reliable “Safe Zone” Assessment: A clear indication of “no risk” offers reassurance that bowel cancer is not present and is unlikely to develop within the next year.

This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.

Comprehensive Cancer Screening Through a Single Test

Pan‑Cancer Detection for Complete Health Protection

Although this document focuses on bowel cancer, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.

Key Advantages Include:

• Holistic Health Monitoring: Simultaneous assessment of bowel cancer risk alongside other major cancers such as Bladder, Breast, Cervical, Kidney, Leukaemia, Liver, Lung, Lymphoma, Ovarian, Pancreatic and Prostate.
• Actionable Insights: Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies.
• One Test, Broad Coverage: A single, non‑invasive test that enhances long‑term health planning and peace of mind.

Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.

About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here